Case studies
Working with our customers to reduce time to market, deliver on quality, provide deep therapeutic expertise, and enhance R&D ROI.
Highlights
We focus our innovation on the factors that matter most — accelerating time to market, reducing costs and enhancing quality. Learn more about how we've helped clients meet and exceed their goals in this selected library of case studies.
Proactive patient retention strategy in a GLP-1 RA trial
Explore how ICON successfully supported a sponsor’s cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate of 97% over 7 years.
A small biotech success story
A small US-based biotech company was in a race to be the first to market with their lead targeted oncology product.
FSP partnership - sustained efficiency and ongoing innovation
The implementation of an FSP model across our partner's project management function, led to 20% cost efficiences and a 30% reduction in client burden.
By taking a site and patient-centric approach, and leveraging advanced tools and real-time data insights, we maximise patient access, recruitment, and retention—ensuring that every trial is conducted with efficiency, agility, and a commitment to improving patient outcomes.
All case studies
Select amongst our broad range of solutions and experience.
Data validation tool delivers 90% reduction on cross-checks time
ICON developed a custom automation tool to cross-check regulatory publishing data for a top 10 global pharmaceutical company managing over 800 monthly requests. The solution reduced verification time by 90%, improving data accuracy and operational efficiency.
Driving data excellence across a global R&D portfolio
A large global pharmaceutical sponsor engaged ICON to stabilise, modernise, and scale Clinical Data Science (CDS) delivery across more than 90 active studies.
Navigating complexity to achieve clinical trial success
ICON is conducting a global, phase 1/2a clinical trial for a small biotech company to evaluate potential treatment for Parkinson disease (PD).
Understanding the breast cancer patient journey
A biopharma company sought a clear, data‑driven view of the HER2⁺ mBC patient journey to improve forecasting, brand strategy, and medical engagement, lacking a unified perspective.
Wearables and remote monitoring case study
A sponsor asked ICON to assess the feasibility and usability of wearables for measuring cough in respiratory patients, ensuring data streams were fit-for-purpose and capturing patient feedback on device acceptance.
Transforming post-marketing safety operations
ICON partnered with a top 10 global pharmaceutical company to support its post-marketing pharmacovigilance
(PV) operations. The partnership evolved from a traditional service model into a fully embedded, strategic
collaboration focused on continuous improvement, cost savings, and global harmonisation.
(PV) operations. The partnership evolved from a traditional service model into a fully embedded, strategic
collaboration focused on continuous improvement, cost savings, and global harmonisation.
Collaboration accelerates rare disease trial delivery
How commitment to partnership overcame historical, layered operational challenges.
A decade-long partnership driving eTMF Hub expansion
A top pharmaceutical company partnered with ICON to standardize TMF management and ensure global inspection readiness. ICON’s customized model enabled a decade-long FSP partnership, driving innovation and leading to eTMF Hub.
Saving a lean biotech more than $4 million with strategic regulatory support
A US-based clinical stage biotech company had several 505(b)(2) NDA assets in development for rare diseases. This very small biotech operated with a lean team which did not have the necessary regulatory expertise to manage regulatory strategy and submissions.
Scaling safety operations for a first-in-market launch
ICON partnered with a leading BioPharma company to support pharmacovigilance (PV) operations for a novel indication product. Following six years of collaboration during clinical development, ICON transitioned to post-marketing support upon product approval and launch in the US and EU.
More patients enrolled faster with fewer sites
Accellacare Site Network reduced the time and cost curve for a respiratory syncytial virus (RSV) vaccine study.
Reducing participant burden in VMS study
ICON supported a proof-of-concept real-world study for participants experiencing bothersome vasomotor symptoms (VMS). The hybrid decentralised clinical trial (DCT) model included both on-site and remote visits, enrolling approximately 1,000 participants across the United States.
Let's collaborate
Discover how ICON's expertise transforms clinical trials.